AMENDMENTS TO THE CLAIMS:

1– 26. (Canceled)

27. (**Currently Amended**) A polynucleotide adjuvant composition comprising:

a polyriboinosinic-polyribocytidylic acid (PIC),

an antibiotic, and

a positive ion,

wherein the composition contains polynucleotide adjuvant composition molecules heterogeneous for at least one of molecular weight or size, wherein the molecular weight is in a molecular weight range of from ~~**about 300,000 to 1,200,000 Daltons**~~ **338,000 to 1,200,000 Daltons** and wherein the size is in a molecular size range of from ~~**about 12.8 to 24.0 Svedbergs**~~ **13.5 to 24.0 Svedbergs**.

28-30. (Canceled)

31. (**Currently Amended**) A polynucleotide adjuvant composition comprising:

a polyriboinosinic-polyribocytidylic acid (PIC),

an antibiotic, and

a positive ion,

wherein the polynucleotide adjuvant composition **molecules** ~~**has**~~ **have** an average molecular weight equal to or greater than **338,000 Daltons** ~~**150,000 Daltons**~~ or have an average molecular size equal to or greater than **13.5 Svedbergs** ~~**9.3 Svedbergs**~~.

32. (**Currently Amended**) The polynucleotide adjuvant composition of claim 31, wherein the average molecular weight is equal to or greater than **500,000 Daltons** ~~**300,000 Daltons**~~ or the average molecular size is equal to or greater than **15 Svedbergs** ~~**12.8 Svedbergs**~~.

33. (Canceled)

34. (**Currently Amended**) The polynucleotide adjuvant composition of any of claims 27, **31 or 32** ~~**to 33**~~, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin.

35. (**Currently Amended**) The polynucleotide adjuvant composition of any of claims 27, **31 or 32** ~~**to 33**~~, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin and the positive ion is calcium, cadmium, lithium, magnesium, cerium, cesium, chromium, cobalt, deuterium, gallium, iodine, iron, or zinc; and wherein the positive ion is the form of an inorganic salt or an organic complex.

36. (**Currently Amended**) The polynucleotide adjuvant composition of any of claims 27, **31 or 32** ~~**to 33**~~, wherein the antibiotic is kanamycin, neomycin, an anthracycline, butirosin sulfate, a gentamicin, hygromycin, amikacin, dibekacin, nebramycin, metrzamide, puromycin, streptomycin, or streptozocin and the source of positive ions is calcium chloride, calcium carbonate, calcium fluoride, calcium hydroxide, calcium phosphates, or calcium sulfate.

37. (**Currently Amended**) The polynucleotide adjuvant composition of any of claims 27, **31 or 32** ~~**to 33**~~, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

38. (**Currently Amended**) A kit comprising the polynucleotide adjuvant composition of any of claims 27**, 31 or 32** ~~**to 33**~~ and an antigenic compound, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

39-45. (**Canceled**)

46. (**Withdrawn, Currently Amended**) A method for enhancing an immune response to an antigenic compound, comprising: administering to a subject a composition comprising an antigenic compound and the polynucleotide adjuvant composition of any of claims 27**, 31 or 32**

~~to 33~~, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

47. (Withdrawn) The method of claim 46, wherein said administering is by parenteral injection, intramuscular injection, intraperitoneal injection, intravenous injection, subcutaneous injection, inhalation, rectal delivery, vaginal delivery, nasal delivery, oral delivery, opthamalic delivery, topical delivery, transdermal delivery or intradermal delivery.

48. (**Withdrawn, Currently Amended**) A method of making an immunogenic composition, the method comprising: combining an antigen with the polynucleotide adjuvant composition of any of claims 27**, 31 or 32** ~~to 33~~ to provide an immunogenic composition.

49. (Withdrawn) The method of claim 48, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

50. (Withdrawn) The method of claim 48, wherein the immunogenic composition is suitable for enhancing an immune response in a human.

51. (Withdrawn) The method of claim 48, wherein the immunogenic composition is suitable for enhancing an immune response in an animal.

52. (New) The polynucleotide adjuvant composition of claim 34, wherein the antibiotic is kanamycin.

53. (New) The polynucleotide adjuvant composition of any of claims 27, 31 or 32, wherein the positive ion is calcium, cadmium, lithium, magnesium, cerium, cesium, chromium, cobalt, deuterium, gallium, iodine, iron, or zinc.

54. (New) The polynucleotide adjuvant composition of claim 53, wherein the positive ion is calcium.

55. (New) An immunogenic composition, comprising:

a polynucleotide adjuvant composition comprising a polyriboinosinic-polyribocytidylic acid (PIC), an antibiotic, and a positive ion; and

an antigenic compound;

wherein the polynucleotide adjuvant composition molecules have an average molecular weight greater than 138,000 Daltons or have an average molecular size greater than 9 Svedbergs.

56. (New) The immunogenic composition of claim 55, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

57. (New) The immunogenic composition of claim 55, wherein the antigenic compound is a human antigen, a non-human animal antigen, a plant antigen, bacterial antigen, a fungal antigen, a viral antigen, a parasite antigen, or a cancer antigen.

58. (New) The immunogenic composition of claim 55, wherein the viral antigen is a rabies antigen.

59. (New) The immunogenic composition of claim 55, wherein the rabies antigen is an inactivated purified rabies antigen.

60. (New) The immunogenic composition of claim 55, wherein polynucleotide adjuvant composition is capable of eliciting an enhanced combined specific humoral and/or cell mediated immune response.

61. (New) The immunogenic composition of claim 55, wherein at least one of the adjuvant composition or the immunogenic composition is in a solid form or a liquid form, wherein the liquid form is a solution or a suspension.

62. (New) The immunogenic composition of claim 55, wherein at least one of the adjuvant composition or the immunogenic composition is freeze-dried.

63. (New) An immunogenic composition, comprising:

a polynucleotide adjuvant composition comprising a polyriboinosinic-polyribocytidylic acid (PIC), an antibiotic, and a positive ion; and

an antigenic compound;

wherein the polynucleotide adjuvant composition molecules have an average molecular weight equal to or greater than 338,000 Daltons or have an average molecular size equal to or greater than 13.5 Svedbergs.

64. (New) The immunogenic composition of claim 63, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

65. (New) The immunogenic composition of claim 63, wherein the antigenic compound is a human antigen, a non-human animal antigen, a plant antigen, bacterial antigen, a fungal antigen, a viral antigen, a parasite antigen, or a cancer antigen.

66. (New) The immunogenic composition of claim 63, wherein the viral antigen is a rabies antigen.

67. (New) The immunogenic composition of claim 63, wherein the rabies antigen is an inactivated purified rabies antigen.

68. (New) The immunogenic composition of claim 63, wherein polynucleotide adjuvant composition is capable of eliciting an enhanced combined specific humoral and/or cell mediated immune response.

69. (New) The immunogenic composition of claim 63, wherein at least one of the adjuvant composition or the immunogenic composition is in a solid form or a liquid form, wherein the liquid form is a solution or a suspension.

70. (New) The immunogenic composition of claim 63, wherein at least one of the adjuvant composition or the immunogenic composition is freeze-dried.

71. (New) An immunogenic composition, comprising:

a polynucleotide adjuvant composition comprising a polyriboinosinic-polyribocytidylic acid (PIC), an antibiotic, and a positive ion; and

an antigenic compound;

wherein the composition contains polynucleotide adjuvant composition molecules heterogeneous for at least one of molecular weight or size, wherein the molecular weight is in a molecular weight range of from 300,000 to 1,200,000 Daltons and wherein the size is in a molecular size range of from 12.8 to 24.0 Svedberg.

72. (New) The immunogenic composition of claim 71, wherein the antibiotic is kanamycin sulfate and the positive ion is provided by calcium chloride.

73. (New) The immunogenic composition of claim 71, wherein the antigenic compound is a human antigen, a non-human animal antigen, a plant antigen, bacterial antigen, a fungal antigen, a viral antigen, a parasite antigen, or a cancer antigen.

74. (New) The immunogenic composition of claim 71, wherein the viral antigen is a rabies antigen.

75. (New) The immunogenic composition of claim 71, wherein the antigenic compound is an inactivated purified rabies antigen.

76. (New) The immunogenic composition of claim 71, wherein polynucleotide adjuvant composition is capable of eliciting an enhanced combined specific humoral and/or cell mediated immune response.

77. (New) The immunogenic composition of claim 71, wherein at least one of the adjuvant composition or the immunogenic composition is in a solid form or a liquid form, wherein the liquid form is a solution or a suspension.

78. (New) The immunogenic composition of claim 71, wherein at least one of the adjuvant composition or the immunogenic composition is freeze-dried.